Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-C5 antibodies for treatment of neuromyelitis optica lineage disorders

A technology for neuromyelitis optica and antibodies, which can be applied to nervous system diseases, antibodies, antibody medical components, etc., and can solve the problems of unmet medical needs in the effective and safe treatment of NMO

Pending Publication Date: 2022-08-05
ALEXION PHARMA INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Given the severity of the disease and limited treatment options, there remains a significant unmet medical need for effective and safe treatments for NMO

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-C5 antibodies for treatment of neuromyelitis optica lineage disorders
  • Anti-C5 antibodies for treatment of neuromyelitis optica lineage disorders
  • Anti-C5 antibodies for treatment of neuromyelitis optica lineage disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0138] Example 1. Efficacy and safety of eculizumab in adult patients with neuromyelitis optica spectrum disorder (NMOSD)

[0139] 1. Research Design

[0140] 1.1. Overall Design

[0141] This is a Phase 3, external placebo-controlled, open-label, multicenter study to evaluate the efficacy and safety of eculizumab in adult patients with NMOSD. Approximately 55 eligible adult patients with NMOSD from North America, Europe, Asia Pacific and Japan participated in the study.

[0142] The study had 4 periods: the screening period, the main treatment period, the long-term extension period, and the safety follow-up period ( figure 1 ). During the screening period, patients are screened for eligibility for up to 6 weeks. When all patients completed the Week 26 visit or terminated early and then completed their end of primary treatment period (EOPT) visit, the primary treatment period ended and the long-term extension period began. All patients continued to receive eculizumab for ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

Methods of clinical treatment of neuromyelitis optica lineage disorder (NMOSD) using anti-C5 antibodies or antigen-binding fragments thereof are provided.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims priority to US Provisional Patent Application No. 62 / 945,644, filed on December 9, 2019, the entire contents of which are incorporated herein by reference for all purposes. [0003] References to Sequence Listings Submitted Electronically [0004] The contents of the electronically submitted Sequence Listing in the ASCII text file (Name: 710476_AX9-007PC_ST25_Sequence_Listing.txt; Size: 56.0 KB; and Date of Creation: December 8, 2020) are incorporated herein by reference in their entirety. Background technique [0005] Neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica (NMO), also known as Devic's Disease or Devic's Syndrome, is a rare and severely disabling central Autoimmune inflammatory disorder of the nervous system (CNS), primarily affecting the optic nerves and spinal cord, often resulting in blindness, mono / pair / tetraplegia, and respiratory failure. NMOSD is cha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/18A61P25/00
CPCC07K16/18A61K2039/545A61P25/00C07K2317/24C07K2317/76C07K2317/52C07K2317/94C07K2317/92A61K2039/505A61P37/06A61K31/436A61K31/519A61K31/52A61K31/5377A61K39/3955A61K2039/54A61K2039/55C07K2317/565
Inventor 克斯廷·艾伦马库斯·扬特斯蒂芬·奥尔蒂斯芬妮·奥布莱恩
Owner ALEXION PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com